Home Publications About the Authors
About the Authors
This website is certified by Health On the Net Foundation. Click to verify.This site complies with the HONcode standard for trustworthy health information:
verify here.
Deutsch Englisch
Contact Impressum Data Protection Login
Home Publications About the Authors
About the Authors
This website is certified by Health On the Net Foundation. Click to verify.This site complies with the HONcode standard for trustworthy health information:
verify here.
Deutsch Englisch
Contact Impressum Data Protection Login
Prof. Dr. Schulz, Martin
Geschäftsführer Pharmazie, Deutsches Arzneiprüfungsinstitut e. V. (DAPI), Berlin
seit Januar 2009
Vorsitzender der Arzneimittelkommission der Deutschen Apotheker (AMK)
seit April 2008
Geschäftsführer für den Bereich Arzneimittel der ABDA, der BAK und des DAV
seit Juli 2005
Honorarprofessor der Goethe-Universität Frankfurt
seit März 2002
Zusätzlich: Geschäftsführer Pharmazie des Deutschen Arzneiprüfungsinstituts (DAPI)
2001 - 2005
Lehrauftrag Klinische Pharmazie an der Goethe-Universität Frankfurt
1993
Fachapotheker für Arzneimittelinformation
1992 - 2008
Stellvertretender Vorsitzender der Arzneimittelkommission der Deutschen Apotheker (AMK)
1989
Fachpharmakologe DGPT
Oktober 1988 - März 2008
Leiter Zentrum für Arzneimittelinformation und Pharmazeutische Praxis (ZAPP) der ABDA
1988
Promotion in Pharmakologie zum Dr. rer. nat.
Oktober 1984 - September 1988
Wissenschaftlicher Mitarbeiter am Pharmakologischen Institut und Institut für Rechtsmedizin, Universität Hamburg
1984 - 1986
Studium der Medizin (Universität Hamburg)
1983 - 1984
Apotheker, Krankenhaus St. Adolf-Stift, Reinbek
Mai 1983
Approbation als Apotheker
1978 - 1982
Studium der Pharmazie (Universität Hamburg)
Publications:
Use of fixed‑dose combination antihypertensives in Germany between 2016 and 2020: an example of guideline inertia
Verordnungsqualität oraler Fluorchinolone in den deutschen Bundesländern 2014 bis 2019
Fixkombinationen von Antihypertensiva auf dem deutschen Markt - Fixkombinationen von ACE-Hemmern, Angiotensin-II-Rezeptorblockern, Betablockern, Calciumkanalblockern und Diuretika
Utilization of drugs with reports on potential efficacy or harm on COVID-19 before, during, and after the first pandemic wave
Infliximab And Etanercept Biosimilars And Originators: Learnings From Regional Market Dynamics In Germany
Wie wirken Generikaquoten? Eine Analyse am Beispiel der HIV Infektion
Changes in utilization of antihypertensive drugs following angiotensin receptor blocker product recalls in Germany
Quality Appraisal of Ambulatory Oral Cephalosporin and Fluoroquinolone Use in the 16 German Federal States from 2014–2019
Utilization of drugs with reports on potential efficacy or harm on COVID-19 before, during, and after the first pandemic wave
Differences In Persistence Rates Between Various Classes Of Antihypertensives In Diabetic Patients
The Value of Access to Pharmacy Claims Data for Healthcare Market Analyses
Impact On Antihypertensive Prescribing After The Dear Healthcare Professional Letter On Increased Risk Of Skin Cancer Related To Hydrochlorothiazide
Learnings from Regional Market Dynamics of Originator and Biosimilar Infliximab and Etanercept in Germany
DAPI-Zahlen aus Berlin. Die 10 häufigsten Wirkstoffe mit pharmazeutischen Bedenken
Incidence of thyroid hormone therapy in patients treated with sunitinib or sorafenib: A cohort study.
Switching the pharmaceutical dosage form of extended-release valproate is associated with therapeutic modification of antiepileptic therapy
Effect of switching branded risedronate to branded or generic alendronate on medication compliance with weekly bisphosphonates: a cohort study utilizing the dapi prescription claims database
Medication persistence with ginkgo biloba drugs of different dosage strengths - Persistenz bei Ginkgo biloba-Arzneimitteln unterschiedlicher Wirkstärke.
Dosage strength is associated with medication persistence with Ginkgo biloba drug products: a cohort study of ambulatory drug claims data in Germany
Innovative Arzneimittel bei Hepatitis C - Was kostet der Zusatznutzen?
Rebate contracts: reasons not to substitute
Innovative Hepatitis-C-Arzneimittel - Was der Zusatznutzen wirklich kostet
Rabattverträge nach § 130a Abs. 8 SGB V: Das Instrument der pharmazeutischen Bedenken
Adherence to Disease Modifying Drugs among Patients with Multiple Sclerosis in Germany: A Retrospective Cohort Study
Hepatitis C - Neue Wirkstoffe im Vergleich
Ad hoc-Auswertungen des DAPI. Dokumentation pharmazeutischer Bedenken in Berlin
DAPI-Zahlen aus Rheinland-Pfalz. Die 10 häufigsten Wirkstoffe mit pharmazeutischen Bedenken
Zielpreise für Leitsubstanzen: Verantwortungsteilung zwischen Arzt und Apotheker
Pharmazeutische Bedenken. Die zehn häufigsten Wirkstoffe in Niedersachsen.
Medication adherence and persistence according to different antihypertensive drug classes: A retrospective cohort study of 255,500 patients
Can claims data help validating drug risk signals? A case report
Evaluation of pharmaceutical concerns in Germany: frequency and potential reasons
Adherence to antihypertensives: feasibility of two self-report instruments to investigate medication-taking behaviour in German community pharmacies.
Temporal synchrony between drug dispensings and adverse drug events? The example of statins & rhabdomyolysis and metamizole or clozapine & agranulocytosis
Oral Antibiotics in Germany and the Netherlands in Primary Care from 2012 – 2016: A Comparison
In search of a standard when analyzing medication adherence in patients with heart failure using claims data: a systematic review.
Comparing outpatient oral antibiotic use in Germany and the Netherlands from 2012 to 2016
Fixkombinationen von Antihypertensiva auf dem deutschen Markt - Fixkombinationen von ACE-Hemmern, Angiotensin-II-Rezeptorblockern, Betablockern, Calciumkanalblockern und Diuretika
Post-mortem analysis of prescription opioids - A follow-up examination by LC–MS/MS with focus on fentanyl
The frequency of photosensitizing drug dispensings in Austria and Germany: A correlation with their photosensitizing potential based on published literature.
Versorgungsforschung: Persistenz und Compliance bei Antihypertensiva
Incidence of thyroid hormone therapy in patients treated with sorafenib or sunitinib
Effect of generic switch on pharmacy refill compliance after ramipril patent expiry – a retrospective study using the DAPI database
Treatment duration (persistence) of basal insulin supported oral therapy (BOT) in Type-2 diabetic patients: comparison of insulin glargine with NPH insulin.
Comparison of different ways of calculation (DDD vs. SPC) to determine persistence and compliance with beta blockers in the DAPI database.
Generic switch after ramipril patent expiry is not associated with decreased pharmacy refill compliance: a retrospective study using the DAPI database.
Association between generic substitution of valproate and therapeutic modification of antiepileptic therapy – a cohort study with time-dependent exposure utilizing the DAPI ambulatory drug claims data
Strategien zur Verbesserung der Einnahmetreue von Medikamenten.
Verbesserung der Therapietreue bei Hypertonikern - eine Aufgabe für den Apotheker
Statine – Verordnungsanalyse und Praxistipps
Prescribing of COX-2 inhibitors in Germany after safety warnings and market withdrawals
Arzneimittelversorgung – Coxibverordnungen nach Marktrücknahmen und Risikomeldungen
Epidemiologische Analyse der Compliance
Impact of rebate contract legislation on generic substitution of valproate – a retrospective study of ambulatory drug dispensing in the DAPI database
Impact of risk communications and market withdrawals on prescribing of cyclooxygenase-2 inhibitors and non-selective nonsteroidal anti-inflammatory drugs
Aktuelle Verordnungen von COX-2-Hemmern in Deutschland
Persistence under treatment with ramipril
Switching from branded alendronate or risedronate to generic alendronate: effect on persistence with bisphosphonate therapy in Germany
Switching from branded alendronate or risedronate to generic alendronate: effect on persistence with bisphosphonate therapy in Germany
Beeinflusst die Umstellung von Risedronat oder Alendronat Originalprodukten auf Generika die Compliance (Persistenz)?
Persistence with basal supported oral therapy - comparison of insulin glargine versus NPH insulin.
Persistence with basal supported oral therapy - comparison of insulin glargine versus NPH insulin.
Pharmacy refill adherence with antidepressants.
Utilizing claims data to assess persistence with antidepressants.
Non-Compliance – das unterschätzte Problem: Neue Möglichkeiten der Erfassung über Datenbankanalysen
Methoden der Datenbank-basierten Persistenz- und Apotheken-basierten Adhärenz-Erfassung am Beispiel von Antihypertensiva
Impact of angiotensin receptor blocker product recalls on antihypertensive prescribing in Germany
“Dear Doctor” Warning Letter (Rote-Hand-Brief) on Hydrochlorothiazide and Its Impact on Antihypertensive Prescription